Evercore says report in FAERS has ‘potential to create confusion’ for Eli Lilly

Evercore ISI notes that the firm is “seeing something in the FDA adverse event database which has potential to create market confusion if not laid out with full background,” namely that a case of hepatic failure has shown up commercially for Foundayo. The case occurred in a 56 year-old male and may have occurred at or before April 15, though it was reported to the FDA on April 30, the analyst noted. Given the overwhelming interest in Eli Lilly’s (LLY) oral launch, the firm adds that it wanted to report the data with context and “without the sensationalism often embedded in FAERS analyses.” Evercore has an In Line rating on Eli Lilly shares.